Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Risperidone in the treatment of behavioral disorders in elderly patients with dementia
Autore:
Gareri, P; Cotroneo, A; Marchisio, U; Curcio, M; De Sarro, G;
Indirizzi:
Univ Catanzaro Magna Graecia, Dept Expt & Clin Med G Salvatore, Chair Pharmacol, Policlin Materdomini, I-88100 Catanzaro, Italy Univ Catanzaro Magna Graecia Catanzaro Italy I-88100 00 Catanzaro, Italy Osped Maria Vittoria, Med Unit, I-10100 Turin, Italy Osped Maria VittoriaTurin Italy I-10100 Med Unit, I-10100 Turin, Italy Casa Cura S Vincenzo, I-88100 Catanzaro, Italy Casa Cura S Vincenzo Catanzaro Italy I-88100 o, I-88100 Catanzaro, Italy
Titolo Testata:
ARCHIVES OF GERONTOLOGY AND GERIATRICS
, , anno: 2001, supplemento:, 7
pagine: 173 - 182
SICI:
0167-4943(2001):<173:RITTOB>2.0.ZU;2-5
Fonte:
ISI
Lingua:
ENG
Soggetto:
ALZHEIMERS-DISEASE; NEUROLEPTIC TREATMENT; ANTIDEPRESSANT DRUGS; GERIATRIC-PATIENTS; DISTURBANCES; MANAGEMENT; PSYCHOSIS; TRIAL; 9-HYDROXYRISPERIDONE; ANTIPSYCHOTICS;
Keywords:
dementia; risperidone-treatment; behavioral disorders in elderly;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
49
Recensione:
Indirizzi per estratti:
Indirizzo: De Sarro, G Univ Catanzaro Magna Graecia, Dept Expt & Clin Med G Salvatore, Chair Pharmacol, Policlin Materdomini, Via Tommaso Campanella 115, I-88100 Catanzaro,Italy Univ Catanzaro Magna Graecia Via Tommaso Campanella 115 Catanzaro Italy I-88100
Citazione:
P. Gareri et al., "Risperidone in the treatment of behavioral disorders in elderly patients with dementia", ARCH GER G, 2001, pp. 173-182

Abstract

The aim of the present study was to evaluate the efficacy of risperidone in the treatment of behavioral disorders in elderly patients with dementia. Thirteen patients with diagnosis of dementia, 7 men (53.8 %) and 6 women (46.2 %), mean age 76.5 +/- 6.3 years, were selected from "Casa di Cura S. Vincenzo", Catanzaro, and from the Medicine Unit of "Ospedale Maria Vittoria", Torino. To evaluate behavioral disturbances, the UCLA Neuropsychiatric Inventory (NPI) was administered at start, and after 4 and 8 weeks. After a wash-out period of 10 days, risperidone was administered in doses of 1 mg/day in the morning; in case of lack of clinical response, dose could be increased to 2 mg/day in divided doses (morning and bedtime) after 4 weeks. Concomitant use of other antipsychotics, antidepressants, mood stabilizers was avoided. Lorazepam (1 to 3 mg/day) could be administered in case of need until the end of the first two weeks. Repeated measure analysis of variance (ANOVA) was used for the statistical evaluation of rating scale scores over time. A good response to risperidone was present in 9 of 13 patients (69.2 %), 5 men and 4 women, a partial response in 3 patients (23.1 %), 2 men and1 woman and no response in 1 woman (7.7 %). The main results were obtainedon agitation, anxiety, euphoria, disinhibition, irritability and wandering. Mean score of NPI was 46.7 +/- 6.9 at start, 14.7 +/- 5.2 after 4 weeks and 11.4 +/- 5.8 after 8 weeks. The decreases in mean score during treatmentwere significant (p < 0.0001). The plasma concentrations of risperidone plus 9-OH-risperidone ranged from 11.5 to 20 nmol/l. To be noticed, the Mini Mental State Examination (MMSE) score did not worsen after risperidone treatment. The results of the present study indicate that risperidone at doses of 1 or 2 mg/day seems to be effective in reducing behavioral symptoms in patients with dementia. It is particularly active on agitation, aggression and wandering. Risperidone also showed a good tolerability and had an efficacy either superior to the traditional neuroleptics or generally comparable,but with fewer side effects.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 19:12:36